Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-70
SponsorFujian Cancer Hospital
About this trial
The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus Non-platinum chemotherapy and Fuzuloparib (PARP inhibitor) induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib in platinum-resistant relapsed/metastatic ovarian cancer.
Eligibility criteria
Qualifiers
Age 18-70; Female;
Pathologically (including histologically) confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (hereinafter referred to as ovarian cancer), recurrence within less than six months after the last treatment with platinum-containing chemotherapy;
Patients have at least one target lesion with measurable dimensions according to RECIST1.1 criteria;
HRR gene mutation confirmed by testing tissue or blood samples;
Disqualifiers
None
Trial design
Treatments tested in this trial
- Immunotherapy（Adebrelimab）
- immunotherapy（Adebrelimab）
Treatment groups
37 Participants
are divided into 1 treatment groupSponsors and collaborators
Fujian Cancer Hospital
Lead sponsor
Fujian Provincial Hospital
Collaborator
Source ClinicalTrials.gov